Century Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Century Therapeutics's estimated annual revenue is currently $35.2M per year.
- Century Therapeutics's estimated revenue per employee is $125,214
- Century Therapeutics's total funding is $560M.
- Century Therapeutics's current valuation is $791.8M. (January 2022)
Employee Data
- Century Therapeutics has 281 Employees.
- Century Therapeutics grew their employee count by 22% last year.
Century Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Century Therapeutics?
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
keywords:N/A
$560M
Total Funding
281
Number of Employees
$35.2M
Revenue (est)
22%
Employee Growth %
$791.8M
Valuation
N/A
Accelerator
Century Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Manager, Financial Planning and Analysis | Reveal Email/Phone |
2 | LIMS Administrator | Reveal Email/Phone |
3 | Associate Manager, eSystems | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
5 | Senior Director, Corporate Strategy, Deal Finance, and Financial Planning Analysis | Reveal Email/Phone |
6 | Executive Director, Nonclinical Development and Safety | Reveal Email/Phone |
7 | Senior Director, Business Development | Reveal Email/Phone |
8 | Senior Director, Head Quality Assurance | Reveal Email/Phone |
9 | Associate Director | Reveal Email/Phone |
10 | Senior Scientist- Analytical Development | Reveal Email/Phone |
Century Therapeutics News
According to Zacks, Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell...
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we...
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we...
Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates Continued Company investment across our iPSC platforms, programs and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221M J ...
PHILADELPHIA, May 5, 2021 /PRNewswire/ -- Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Joe Jimenez as Board Chair and Cynthia Butitta as a new Independent Direc ...
Other Companies in Philadelphia
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $83.8M | 282 | 7% | N/A |
#2 | $83.8M | 282 | 5% | N/A |
#3 | $63.8M | 283 | 1% | N/A |
#4 | $56.2M | 284 | 7% | N/A |
#5 | $84.6M | 285 | 13% | N/A |